Role of VEGF-A and its receptors in sporadic and MEN2-associated pheochromocytoma
dc.contributor.author | Vargas, Carla Vaz Ferreira | pt_BR |
dc.contributor.author | Siqueira, Débora Rodrigues | pt_BR |
dc.contributor.author | Romitti, Mirian | pt_BR |
dc.contributor.author | Ceolin, Lucieli | pt_BR |
dc.contributor.author | Assis Brasil, Beatriz Maria de Azevedo | pt_BR |
dc.contributor.author | Meurer, Luíse | pt_BR |
dc.contributor.author | Capp, Clarissa | pt_BR |
dc.contributor.author | Maia, Ana Luiza Silva | pt_BR |
dc.date.accessioned | 2015-03-04T01:58:09Z | pt_BR |
dc.date.issued | 2014 | pt_BR |
dc.identifier.issn | 1422-0067 | pt_BR |
dc.identifier.uri | http://hdl.handle.net/10183/111627 | pt_BR |
dc.description.abstract | Pheochromocytoma (PHEO), a rare catecholamine producing tumor arising from the chromaffin cells, may occurs sporadically (76%–80%) or as part of inherited syndromes (20%–24%). Angiogenesis is a fundamental step in tumor proliferation and vascular endothelial growth factor (VEGF-A) is the most well-characterized angiogenic factor. The role of angiogenic markers in PHEO is not fully understood; investigations were therefore made to evaluate the expression of VEGF-A and its receptors in PHEO and correlate to clinical parameters. Twenty-nine samples of PHEO were evaluated for VEGF-A, VEGF receptor-1 (VEGFR-1) VEGFR-2 expression and microvessel density (MVD) by immunohistochemistry. Clinical data were reviewed in medical records. The mean age of patients was 38 ± 14 years, and 69% were woman. VEGF-A, VEGFR-1 and VEGFR-2 staining were detected in nearly all PHEO samples. No significant correlation was observed between VEGF-A, VEGFR-1, VEGFR-2 expression or MVD and age at diagnosis, tumor size or sporadic and hereditary PHEO. However, the levels of expression of these molecules were significantly higher in malignant PHEO samples (p = 0.027,p = 0.003 and p = 0.026, respectively).VEGF-A and its receptors were shown to be up-regulated in malignant PHEO, suggesting that these molecules might be considered as therapeutic targets for unresectable or metastatic tumors. | en |
dc.format.mimetype | application/pdf | pt_BR |
dc.language.iso | eng | pt_BR |
dc.relation.ispartof | International journal of molecular sciences. Basel. Vol. 15, no. 4 (Apr. 2014), p. 5323-5336 | pt_BR |
dc.rights | Open Access | en |
dc.subject | Feocromocitoma | pt_BR |
dc.subject | Pheocromocytoma | en |
dc.subject | Neoplasia endócrina múltipla tipo 2a | pt_BR |
dc.subject | VEGF-A | en |
dc.subject | Microvessel density | en |
dc.subject | Receptor 1 do fator de crescimento do endotélio vascular | pt_BR |
dc.subject | Receptor 2 do fator de crescimento do endotélio vascular | pt_BR |
dc.title | Role of VEGF-A and its receptors in sporadic and MEN2-associated pheochromocytoma | pt_BR |
dc.type | Artigo de periódico | pt_BR |
dc.identifier.nrb | 000943252 | pt_BR |
dc.type.origin | Estrangeiro | pt_BR |
Este item está licenciado na Creative Commons License
-
Artigos de Periódicos (39096)Ciências da Saúde (10544)